Response Genetics, Inc. (RGDX) Announces New President to Assist in Execution of Business Strategy and Operations
Response Genetics, a company focused on the development and commercialization of molecular diagnostic tests for cancer, today announced the appointment of Christine Meda as the company’s president, replacing Kathleen Danenberg, who will continue to act as CEO. Meda’s nearly 30 years of experience in strategic partnering, operations and marketing for Response Genetics will fuel her ability to help in the execution of the company’s strategy and operations on a day-to-day basis. “I am pleased to be joining Response Genetics, a company with a unique platform technology and differentiated product offering. I look forward to applying my skills and experience knowing…